Theoretical and clinical aspects of prostaglandins application in glaucoma therapy;Teoretyczne i kliniczne aspekty zastosowania prostaglandyn w leczeniu jaskry

Klinika Oczna

Volumn 106, Issue 3, 2004, Pages 352-359

  Wierzbowska, Joanna ^a,b   Stankiewicz, Andrzej ^a  

^a Z Kliniki Okulistycznej Wojskowego   (Poland)

^b MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Extracellular matrix of ciliary muscle; Glaucoma; Matrix metalloproteinases; Prostaglandins analogues; Uveoscleral outflow

Indexed keywords

AMIDE; BIMATOPROST; CLOPROSTENOL; DRUG DERIVATIVE; LATANOPROST; LIPID; PROSTAGLANDIN F; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN RECEPTOR; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER;

DRUG EFFECT; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; METABOLISM; PATHOPHYSIOLOGY; REVIEW; TREATMENT OUTCOME;

AMIDES; CLOPROSTENOL; DINOPROST; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; PROSTAGLANDINS F; PROSTAGLANDINS F, SYNTHETIC; RECEPTORS, PROSTAGLANDIN; TREATMENT OUTCOME;

EID: 16644392255     PISSN: 00232157     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Alexander J. P., Samples J. R., Van Buskirk et al.: Expression of matrix metalloproteinases and inhibitors by human trabecular meshwork. Invest. Ophthalmol. Vis. Sci., 1991, 32, 172-180.
2. Ambache N.: Irin, a smooth muscle contracting substance present in rabbit iris. J. Physiol., 1955, 129, 65-66.
3. Bill A.: The aqueous humor drainage mechanism in the cynomolgus monkey (Macaca irus) with evidence for unconventional routes. Invest. Ophthalmol., 1965, 4, 911-919.
4. Bucci M. G., the Italian Latano-prost Study Group: Intraocular pressure-lowering effects of latano-prost monotherapy versus latanoprost or pilocarpine in combination with timolol, a randomized, observer-masked multicenter study in patients with open-angle glaucoma. J. Glaucoma, 1999, 8, 24-30.
5. Camras C. B., Alm A., Watson R et al.: Latanoprost, a Prostaglandin Analog, for Glaucoma Therapy. Ophthalmology, 1996, 103, 1916-1924.
6. Chew P. T. K., Hung P. T., Aung T.: Efficacy of Latano-prost in Reducing Intraocular Pressure in Patients with Primary Angle-Closure Glaucoma. Surv. Ophthalmol., 2002, 47 (Suppl. 1), S125-S128.
7. Czechowicz-Janicka K., Terelak-Borys B., Krajewska M. i wsp.: 3-letnie doświadczenia z Xalatanem w leczeniu JPOK. Praca wygłoszona na III Sympozjum Jaskry, 10-12.10.2002 r., Wrocław, Polska.
8. Drance S. M., Crichton A., Mills R. P.: Comparison of the effect of latanoprost 0,005% and timolol 0,5% on the calculated ocular perfusion pressure in patients with normal tension glaucoma. Am. J. Ophthalmol., 1998, 125, 585-592.
9. Enyedi L. B., Freedma S. F.: Latanoprost for the Treatment of Pediatric Glaucoma. Surv. Ophthalmol., 2002, 47 (Suppl. 1), S129-S132.
10. Hellberg M. R., McLaughlin M. A., Sharif N. A. et al.: Identification and Characterisation of the Ocular Hypotensive Efficacy Of Travoprost, a Potent and Selective FP Prostaglandin Receptor Agonist, and AL-6598, a DP Prostaglandin Receptor Agonist. Surv. Ophthalmol., 2002, 47 (Suppl. 1), S13-S33.
11. Hellberg M. R., Sallee V. L., McLaughlin M. A. et al.: Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J. Ocular. Pharmacol. Ther., 2001, 17 (5), 421-432.
12. Honrubia F. M., Larsson L. I., Spiegel D. et al.: A comparison of the effects on intraocular pressure of latanoprost 0,005% and the fixed combination of dorzolamide 2% and timolol 0,5% in patients with open-angle glaucoma. Acta Ophthalmol. Scand., 2002, 80, 635-641.
13. Kanno M., Araie M., Tomita K. et al.: Effects of topical nipradilol, a beta-blocking agent with alpha-blocking and nitroglycerin-like activities, on aqueous humour dynamics and fundus circulation. Invest. Ophthalmol. Vis. Sci., 1998, 39, 736-743.
14. Kashiwagi K., Lindsay J. D., Kashiwagi F. et al.: Extracellular matrix changes induced by prostaglandins in cultured human ciliary muscle cells. Invest Ophthalmol Vis Sci., 1995, 36 (Suppl.), S729.
15. Konstas A. G. P., Kozobolis V. P., Tersis I. et al.: The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma. Eye, 2003, 17, 41-46.
16. Lindsey J. D., Gaton D. D., Sagara T. et al.: Reduced TIGR/Myocilin Protein in the Monkey Ciliary Muscle after Topical Prostaglandin F2-alpha Treatment. Invest. Ophthalmol. Vis. Sci., 2001, 42, 1781-1786.
17. Lindsey J. D., Kashiwagi K., Kashiwagi F. et al.: Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: Implications for uveoscleral outflow. Surv Ophthalmol., 1997, 42, S53-S59.
18. Lutjen-Drecoll E., Shimizu T., Rohrbach M. et al.: Quantitative analysis of "plaque material" between ciliary muscle tip in normal and glaucomatous eyes. Exp. Eye Res., 1986, 42, 457-465.
19. 2 binding sites in the human eye. Br. J. Ophthalmol., 1992, 76, 210-213.
20. Miyake K., Ota I., Ibaraki N. et al.: Enhanced disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia. Arch. Ophthalmol., 2001, 119, 387-394.
21. Netland P. A., Landry T., Sullivan E. K. et al.: Travoprost Compared With Latanoprost and Timolol in Patients With Open-angle Glaucoma or Ocular Hypertension. Am. J. Ophthalmol., 2001, 132, 472-484.
22. Niżankowska M., Turno-Krȩcicka A., Muzyka M.: Czynniki ryzyka naczyniowego w jaskrze. Czy obniżaja̧c ciśnienie wewna̧trzgałkowe możemy zahamować postȩp neuropatii jaskrowej? Okulistyka, 1998, 2, 6-10.
23. Orzalesi N., Rossetti L., Bottoli A. et al.: The Effect of Latanoprost, Brimonidine, and a Fixed Combination of Timolol and Dorzolamide on Circadian Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension. Arch. Ophthalmol., 2003, 121, 453-457.
24. Parrish R. K., Palmberg P., Sheu W. P.: A comparison of Latanoprost, Bimatoprost and Travoprost in Patients With Elevated Intraocular Pressure: A 12-week, randomized, Masked-evaluator Multicenter Study. Am. J. Ophthalmol., 2003, 135, 688-703.
25. Schmidt K. G.: Prostaglandin Receptors in Ocular Tissues and their Pharmacological Influence. In: Orgul S., Flammer J.: Pharmacotherapy in Glaucoma, Verlag Hans Huber, Bern, 2000, 159-168.
26. Semeniuk H., Klemarczyk A., Gawrońska J. i wsp.: Skuteczność Xalatanu wjaskrze z trudno reguluja̧cym siȩ ciśnieniem - obserwacje własne. Okulistyka, 2000, numer specjalny, kwiecień, 12-15.
27. Toris C. B., Yablonski M. E., Camras C. B., et al.: Uveoscleral outflow decreases with age in ocular normotensive humous. Invest. Ophthalmol. Vis. Sci., 1996, 37 (ARVO Suppl.), 410.
28. Vertrugo M., Cantatore F., Gigante G. et al.: Latanoprost 0,005% in PO-AG: effects on IOP and ocular blood flow. Acta Ophthalmol Scand., 1998, 227 (Suppl.), 40-41.
29. Woodward D. F., Lawrence R. A., Fairbairn C. E. et al.: Intraocular pressure effects of selective prostanoid receptor agonists involve different receptor subtypes according to radioligand binding studies. J. Lipid. Mediat., 1993, 6, 545-553. Pozostałe piśmiennictwo u autorów.